CA-AERA-TECHNOLOGY
24.9.2020 14:02:16 CEST | Business Wire | Press release
Aera Technology today announced the general availability of the Aera Cognitive Operating System™, the world's first cloud platform for Cognitive Automation . In extending availability beyond current customers and partners, including Merck, RB, and Unilever, Aera meets the growing need of companies whose operations have been impacted by changing or uncertain market conditions.
“We’ve worked with the world's largest organizations and complex supply chains to demonstrate the value of Cognitive Automation at scale. This tight collaboration has enabled us to build the Aera Cognitive Operating System™, which is now easy to implement and scale, and therefore available to an even wider range of companies,” said Frederic Laluyaux, CEO of Aera Technology.
Alessandro de Luca, CIO of Healthcare, Merck Group, noted, “We are all running on much shorter cycles in this dynamic world, and it is impossible to process everything manually or on legacy systems. Aera's Cognitive Operating System™ has made a real difference in our ability to implement and operate a best-in-Class IBP process. This, combined with the fact that we could rely on a single, intelligent source of truth, gave us a springboard to agility.”
“Cognitive Automation plays a large role in the 4th industrial revolution,” said Nokuthula Lukhele, Project Lead, Data, and Digital Transformation, World Economic Forum. “The future of agility needs to be at the edge of decision making, and these technologies enable that,” she added.
The Aera Cognitive Operating System™ augments and enhances human decisions, providing a centralized corporate brain - adding agility to enterprise systems. By applying data crawling, machine learning, and industry models, Aera’s system makes real-time recommendations, predicts outcomes, and acts autonomously to aid complex decisions - from inventory optimization and touchless planning to order management and trade promotions.
“There is a limit of what the human mind can do with the volume of data and analytics needed to optimize a supply chain,” said Bish Sen, Head of Supply Chain Beauty & Personal Care, Transformation, Planning & Engineering at Unilever. “This is where agility is more important than accuracy, and Cognitive Automation can help unlock those levels of agility.”
“Designing and managing a supply chain that balances customer service, cost, and resiliency requires a model that constantly measures and reacts to value at risk. Kearney’s Sense & Pivot approach, combined with Aera’s Cognitive Operating System™, provides a proven solution agile enough to respond to this challenge by delivering real-time Cognitive Automation at scale for corporate boards and supply chain leaders.” - Suketu Gandhi, Partner, Global Leader - Digital Supply Chain, Kearney.
Aera Technology is hosting the Cognitive Automation Summit on September 24, 2020. This first summit dedicated to Cognitive Automation offers a unique opportunity to understand how the tectonic shift in cloud-scale and in artificial intelligence, along with radical market volatility are forcing enterprises to redefine agility. Thought leaders and pioneers from world-leading organizations will share how they leverage Aera’s Cognitive Operating System™ to achieve previously unattainable levels of financial and operational performance - without trade-offs.
For more information, visit https://cognitiveautomationsummit.com/ .
Aera also announced this week the launch of Aera Developer™, a self-service integrated development environment, which has been purpose-built for implementing Cognitive Automation at scale. It integrates each component of Data, Science, Process, and Change, so that it has all of the capabilities necessary for building Cognitive Skills, all rolled into one seamless user experience.
About Aera Technology
Aera Technology delivers the Cognitive Operating System™ that enables the Self-Driving Enterprise™. Aera understands how businesses work; makes real-time recommendations; predicts outcomes; and acts autonomously. Using proprietary data crawling, industry models, machine learning and artificial intelligence, Aera is revolutionizing how people relate to data and how organizations function. Headquartered in Mountain View, California, Aera services some of the world's largest enterprises from its global offices located in San Francisco, Bucharest, Cluj-Napoca, Paris, Munich, London, Pune, and Sydney. For more information about Aera, please visit www.aeratechnology.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005298/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom